Breaking News

Memo Therapeutics Collaborates with Northway Biotechpharma

Will fast-track cGMP manufacturing of a SARS-CoV-2 neutralizing antibody.

By: Contract Pharma

Contract Pharma Staff

Swiss biotech company Memo Therapeutics AG (MTx) and Northway Biotechpharma, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have formed a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a four-month fast-track process.   MTX-COVAB is a fully human, highly potent antibody isolated from clinically selected convalescent COVID-19 donors with picomolar neutralizing activity against wild-type SARS-CoV-2, as well as newly described mutant...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters